Do Estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women

Chi Un Pae, Laura Mandelli, Changsu Han, Byung-Joo Ham, Prakash S. Masand, Ashwin A. Patkar, David C. Steffens, Diana De Ronchi, Alessandro Serretti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: A hypo-estrogenic status, as that occurring with menopause, has been proposed to negatively affect cognitive function in post-menopause women. Nevertheless, little is known about the improvement of cognitive functions during antidepressant treatment in post-menopausal women with major depressive disorder (MDD) and its relation with hormonal changes. Hence, this study aimed to investigate the role of menopausal status including the level of sex hormones on cognitive function during antidepressant treatment. Design and settings: Thirty-nine female patients (n=17 in pre-menopause; n=22 in post-menopause) with MDD based on DSM-IV criteria and who were not on hormonal replacement therapies participated in a prospective, 6-week, open-label naturalistic study. All patients were recruited in a university-based hospital. The Hamilton rating scale for Depression (HAMD), Montgomery-Åsberg Depression Rating Scale (MADRS) and the Cognitive Failure Questionnaire (CFQ) were administered at baseline, week 1, week 3, and week 6. Levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were collected at baseline visit. Results: Cognitive functioning improved during antidepressant treatment in the overall sample (p=0.00001). In post-menopausal women, E2 levels were strongly correlated with CFQ scores at each measurement. After controlling for depression severity, E2 levels maintained a significant association with the baseline CFQ scores (regression analysis: β=-0.55 p=0.010; correlation: R=-0.54). In addition, the reduction of CFQ scores during antidepressant treatment was significantly associated with E2 levels (p=0.021), independently from the improvement of depressive symptoms, which however had a strong effect (p=0.0003). Nevertheless, we failed to find any association of CFQ score with sex hormones in pre-menopausal women. Main findings: In post-menopausal women, the CFQ scores were correlated with E2 levels and the reduction of CFQ score during antidepressant treatment was also dependent on E2 levels, even controlling for depressive symptoms severity. Conclusion: The present study further supports a crucial role of E2 on the cognitive function in post-menopause women. Moreover, our results suggest that E2 may influence the improvement of cognitive function in post-menopause women with MDD, during treatment with antidepressants.

Original languageEnglish
Pages (from-to)500-506
Number of pages7
JournalNeuroendocrinology Letters
Volume29
Issue number4
Publication statusPublished - 2008 Aug 1

Fingerprint

Major Depressive Disorder
Cognition
Antidepressive Agents
Estradiol
Postmenopause
Depression
Gonadal Steroid Hormones
Therapeutics
Premenopause
Follicle Stimulating Hormone
Menopause
Luteinizing Hormone
Surveys and Questionnaires
Diagnostic and Statistical Manual of Mental Disorders
Regression Analysis

Keywords

  • Cognitive function
  • Extradiol
  • Major depressive disorder
  • Menopause
  • Sex harmones

ASJC Scopus subject areas

  • Endocrinology
  • Endocrine and Autonomic Systems
  • Endocrinology, Diabetes and Metabolism
  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

Do Estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. / Pae, Chi Un; Mandelli, Laura; Han, Changsu; Ham, Byung-Joo; Masand, Prakash S.; Patkar, Ashwin A.; Steffens, David C.; De Ronchi, Diana; Serretti, Alessandro.

In: Neuroendocrinology Letters, Vol. 29, No. 4, 01.08.2008, p. 500-506.

Research output: Contribution to journalArticle

Pae, Chi Un ; Mandelli, Laura ; Han, Changsu ; Ham, Byung-Joo ; Masand, Prakash S. ; Patkar, Ashwin A. ; Steffens, David C. ; De Ronchi, Diana ; Serretti, Alessandro. / Do Estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. In: Neuroendocrinology Letters. 2008 ; Vol. 29, No. 4. pp. 500-506.
@article{18ade1a085c2464186a81e7bb7f19fd9,
title = "Do Estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women",
abstract = "Objectives: A hypo-estrogenic status, as that occurring with menopause, has been proposed to negatively affect cognitive function in post-menopause women. Nevertheless, little is known about the improvement of cognitive functions during antidepressant treatment in post-menopausal women with major depressive disorder (MDD) and its relation with hormonal changes. Hence, this study aimed to investigate the role of menopausal status including the level of sex hormones on cognitive function during antidepressant treatment. Design and settings: Thirty-nine female patients (n=17 in pre-menopause; n=22 in post-menopause) with MDD based on DSM-IV criteria and who were not on hormonal replacement therapies participated in a prospective, 6-week, open-label naturalistic study. All patients were recruited in a university-based hospital. The Hamilton rating scale for Depression (HAMD), Montgomery-{\AA}sberg Depression Rating Scale (MADRS) and the Cognitive Failure Questionnaire (CFQ) were administered at baseline, week 1, week 3, and week 6. Levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were collected at baseline visit. Results: Cognitive functioning improved during antidepressant treatment in the overall sample (p=0.00001). In post-menopausal women, E2 levels were strongly correlated with CFQ scores at each measurement. After controlling for depression severity, E2 levels maintained a significant association with the baseline CFQ scores (regression analysis: β=-0.55 p=0.010; correlation: R=-0.54). In addition, the reduction of CFQ scores during antidepressant treatment was significantly associated with E2 levels (p=0.021), independently from the improvement of depressive symptoms, which however had a strong effect (p=0.0003). Nevertheless, we failed to find any association of CFQ score with sex hormones in pre-menopausal women. Main findings: In post-menopausal women, the CFQ scores were correlated with E2 levels and the reduction of CFQ score during antidepressant treatment was also dependent on E2 levels, even controlling for depressive symptoms severity. Conclusion: The present study further supports a crucial role of E2 on the cognitive function in post-menopause women. Moreover, our results suggest that E2 may influence the improvement of cognitive function in post-menopause women with MDD, during treatment with antidepressants.",
keywords = "Cognitive function, Extradiol, Major depressive disorder, Menopause, Sex harmones",
author = "Pae, {Chi Un} and Laura Mandelli and Changsu Han and Byung-Joo Ham and Masand, {Prakash S.} and Patkar, {Ashwin A.} and Steffens, {David C.} and {De Ronchi}, Diana and Alessandro Serretti",
year = "2008",
month = "8",
day = "1",
language = "English",
volume = "29",
pages = "500--506",
journal = "Neuroendocrinology Letters",
issn = "0172-780X",
publisher = "Maghira and Maas Publications",
number = "4",

}

TY - JOUR

T1 - Do Estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women

AU - Pae, Chi Un

AU - Mandelli, Laura

AU - Han, Changsu

AU - Ham, Byung-Joo

AU - Masand, Prakash S.

AU - Patkar, Ashwin A.

AU - Steffens, David C.

AU - De Ronchi, Diana

AU - Serretti, Alessandro

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Objectives: A hypo-estrogenic status, as that occurring with menopause, has been proposed to negatively affect cognitive function in post-menopause women. Nevertheless, little is known about the improvement of cognitive functions during antidepressant treatment in post-menopausal women with major depressive disorder (MDD) and its relation with hormonal changes. Hence, this study aimed to investigate the role of menopausal status including the level of sex hormones on cognitive function during antidepressant treatment. Design and settings: Thirty-nine female patients (n=17 in pre-menopause; n=22 in post-menopause) with MDD based on DSM-IV criteria and who were not on hormonal replacement therapies participated in a prospective, 6-week, open-label naturalistic study. All patients were recruited in a university-based hospital. The Hamilton rating scale for Depression (HAMD), Montgomery-Åsberg Depression Rating Scale (MADRS) and the Cognitive Failure Questionnaire (CFQ) were administered at baseline, week 1, week 3, and week 6. Levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were collected at baseline visit. Results: Cognitive functioning improved during antidepressant treatment in the overall sample (p=0.00001). In post-menopausal women, E2 levels were strongly correlated with CFQ scores at each measurement. After controlling for depression severity, E2 levels maintained a significant association with the baseline CFQ scores (regression analysis: β=-0.55 p=0.010; correlation: R=-0.54). In addition, the reduction of CFQ scores during antidepressant treatment was significantly associated with E2 levels (p=0.021), independently from the improvement of depressive symptoms, which however had a strong effect (p=0.0003). Nevertheless, we failed to find any association of CFQ score with sex hormones in pre-menopausal women. Main findings: In post-menopausal women, the CFQ scores were correlated with E2 levels and the reduction of CFQ score during antidepressant treatment was also dependent on E2 levels, even controlling for depressive symptoms severity. Conclusion: The present study further supports a crucial role of E2 on the cognitive function in post-menopause women. Moreover, our results suggest that E2 may influence the improvement of cognitive function in post-menopause women with MDD, during treatment with antidepressants.

AB - Objectives: A hypo-estrogenic status, as that occurring with menopause, has been proposed to negatively affect cognitive function in post-menopause women. Nevertheless, little is known about the improvement of cognitive functions during antidepressant treatment in post-menopausal women with major depressive disorder (MDD) and its relation with hormonal changes. Hence, this study aimed to investigate the role of menopausal status including the level of sex hormones on cognitive function during antidepressant treatment. Design and settings: Thirty-nine female patients (n=17 in pre-menopause; n=22 in post-menopause) with MDD based on DSM-IV criteria and who were not on hormonal replacement therapies participated in a prospective, 6-week, open-label naturalistic study. All patients were recruited in a university-based hospital. The Hamilton rating scale for Depression (HAMD), Montgomery-Åsberg Depression Rating Scale (MADRS) and the Cognitive Failure Questionnaire (CFQ) were administered at baseline, week 1, week 3, and week 6. Levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) were collected at baseline visit. Results: Cognitive functioning improved during antidepressant treatment in the overall sample (p=0.00001). In post-menopausal women, E2 levels were strongly correlated with CFQ scores at each measurement. After controlling for depression severity, E2 levels maintained a significant association with the baseline CFQ scores (regression analysis: β=-0.55 p=0.010; correlation: R=-0.54). In addition, the reduction of CFQ scores during antidepressant treatment was significantly associated with E2 levels (p=0.021), independently from the improvement of depressive symptoms, which however had a strong effect (p=0.0003). Nevertheless, we failed to find any association of CFQ score with sex hormones in pre-menopausal women. Main findings: In post-menopausal women, the CFQ scores were correlated with E2 levels and the reduction of CFQ score during antidepressant treatment was also dependent on E2 levels, even controlling for depressive symptoms severity. Conclusion: The present study further supports a crucial role of E2 on the cognitive function in post-menopause women. Moreover, our results suggest that E2 may influence the improvement of cognitive function in post-menopause women with MDD, during treatment with antidepressants.

KW - Cognitive function

KW - Extradiol

KW - Major depressive disorder

KW - Menopause

KW - Sex harmones

UR - http://www.scopus.com/inward/record.url?scp=54349125062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349125062&partnerID=8YFLogxK

M3 - Article

C2 - 18766158

AN - SCOPUS:54349125062

VL - 29

SP - 500

EP - 506

JO - Neuroendocrinology Letters

JF - Neuroendocrinology Letters

SN - 0172-780X

IS - 4

ER -